Published in Aust N Z J Psychiatry on November 18, 2010
Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review. Curr Neuropharmacol (2012) 1.19
The 5-year course of obsessive-compulsive symptoms and obsessive-compulsive disorder in first-episode schizophrenia and related disorders. Schizophr Bull (2011) 0.98
Comorbid Obsessive-Compulsive Symptoms in Schizophrenia: Insight into Pathomechanisms Facilitates Treatment. Adv Med (2014) 0.97
Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors. Front Pharmacol (2013) 0.97
Obsessive-Compulsive Disorder, Psychosis, and Bipolarity: A Longitudinal Cohort and Multigenerational Family Study. Schizophr Bull (2014) 0.94
Obsessive compulsive symptoms in individuals at clinical risk for psychosis: association with depressive symptoms and suicidal ideation. Schizophr Res (2012) 0.85
Prevalence and clinical characteristics of patients with obsessive-compulsive disorder in first-episode psychosis. BMC Psychiatry (2013) 0.77
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Genome-wide association analysis identifies 13 new risk loci for schizophrenia. Nat Genet (2013) 7.44
Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophr Res (2013) 3.01
The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging Behav (2014) 1.90
The five-factor model of the Positive and Negative Syndrome Scale II: a ten-fold cross-validation of a revised model. Schizophr Res (2006) 1.66
Suicide risk in placebo-controlled trials of treatment for acute manic episode and prevention of manic-depressive episode. Am J Psychiatry (2005) 1.52
Cannabis use and callosal white matter structure and integrity in recent-onset schizophrenia. Psychiatry Res (2010) 1.52
Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis. Schizophr Res (2009) 1.43
Diffusion tensor imaging in the early phase of schizophrenia: what have we learned? J Psychiatr Res (2010) 1.32
Cognitive behavioral therapy for subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical trial. Schizophr Bull (2012) 1.22
Genetic Risk and Outcome of Psychosis (GROUP), a multi-site longitudinal cohort study focused on gene-environment interaction: objectives, sample characteristics, recruitment and assessment methods. Int J Methods Psychiatr Res (2012) 1.21
The five-factor model of the Positive and Negative Syndrome Scale I: confirmatory factor analysis fails to confirm 25 published five-factor solutions. Schizophr Res (2006) 1.18
Whither the attenuated psychosis syndrome? Schizophr Bull (2012) 1.12
Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations. Schizophr Bull (2014) 1.10
Disability in people clinically at high risk of psychosis. Br J Psychiatry (2010) 1.10
Environmental factors and social adjustment as predictors of a first psychosis in subjects at ultra high risk. Schizophr Res (2011) 1.10
Risperidone-induced leucopenia and neutropenia: a case report. Eur Psychiatry (2004) 1.07
Association between the DTNBP1 gene and intelligence: a case-control study in young patients with schizophrenia and related disorders and unaffected siblings. Behav Brain Funct (2007) 1.06
Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J Clin Endocrinol Metab (2007) 1.06
Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: a meta-analysis. Psychiatry Res (2012) 1.05
The validity of the 16-item version of the Prodromal Questionnaire (PQ-16) to screen for ultra high risk of developing psychosis in the general help-seeking population. Schizophr Bull (2012) 1.05
White matter fibertracking in first-episode schizophrenia, schizoaffective patients and subjects at ultra-high risk of psychosis. Neuropsychobiology (2008) 1.02
Ultra high-risk state for psychosis and non-transition: a systematic review. Schizophr Res (2011) 1.02
Age of onset of cannabis use is associated with age of onset of high-risk symptoms for psychosis. Can J Psychiatry (2010) 1.00
The 5-year course of obsessive-compulsive symptoms and obsessive-compulsive disorder in first-episode schizophrenia and related disorders. Schizophr Bull (2011) 0.98
White matter abnormalities in adults with 22q11 deletion syndrome with and without schizophrenia. Schizophr Res (2011) 0.94
New data and an old puzzle: the negative association between schizophrenia and rheumatoid arthritis. Int J Epidemiol (2015) 0.93
Symptomatology and neuropsychological functioning in cannabis using subjects at ultra-high risk for developing psychosis and healthy controls. Aust N Z J Psychiatry (2010) 0.93
Insight in psychosis: relationship with neurocognition, social cognition and clinical symptoms depends on phase of illness. Schizophr Bull (2010) 0.92
AMPT-induced monoamine depletion in humans: evaluation of two alternative [123I]IBZM SPECT procedures. Eur J Nucl Med Mol Imaging (2008) 0.91
Pericardial and bilateral pleural effusion associated with clozapine treatment. Eur Psychiatry (2004) 0.90
Off-label second generation antipsychotics for impulse regulation disorders: a review. Psychopharmacol Bull (2010) 0.88
Polyunsaturated fatty acid concentration predicts myelin integrity in early-phase psychosis. Schizophr Bull (2012) 0.88
Reduced parietal P300 amplitude is associated with an increased risk for a first psychotic episode. Biol Psychiatry (2010) 0.88
A genome-wide association analysis of a broad psychosis phenotype identifies three loci for further investigation. Biol Psychiatry (2013) 0.87
Reliability and validity of the Yale-Brown Obsessive-Compulsive Scale in schizophrenia patients. Psychopharmacol Bull (2006) 0.87
The effect of motivational interviewing on medication adherence and hospitalization rates in nonadherent patients with multi-episode schizophrenia. Schizophr Bull (2013) 0.86
Adult attachment and psychotic phenomenology in clinical and non-clinical samples: a systematic review. Psychol Psychother (2013) 0.86
White matter connectivity and psychosis in ultra-high-risk subjects: a diffusion tensor fiber tracking study. Psychiatry Res (2010) 0.86
Duration of untreated psychosis and outcome of schizophrenia: delay in intensive psychosocial treatment versus delay in treatment with antipsychotic medication. Schizophr Bull (2003) 0.86
Schizophrenia spectrum disorders in later life: prevalence and distribution of age at onset and sex in a dutch catchment area. Am J Geriatr Psychiatry (2012) 0.86
Pathways to psychosis: help-seeking behavior in the prodromal phase. Schizophr Res (2011) 0.85
Sexual dysfunction and hormonal changes in first episode psychosis patients on olanzapine or risperidone. Psychoneuroendocrinology (2009) 0.85
Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling study. J Clin Psychiatry (2011) 0.85
Schizophrenia-associated neural growth factors in peripheral blood. A review. Eur Neuropsychopharmacol (2006) 0.85
The revised dopamine hypothesis of schizophrenia: evidence from pharmacological MRI studies with atypical antipsychotic medication. Psychopharmacol Bull (2008) 0.85
Moving beyond transition outcomes: meta-analysis of remission rates in individuals at high clinical risk for psychosis. Psychiatry Res (2013) 0.85
Proton magnetic resonance spectroscopy in 22q11 deletion syndrome. PLoS One (2011) 0.85
Cannabis use in patients at clinical high risk of psychosis: impact on prodromal symptoms and transition to psychosis. Curr Pharm Des (2012) 0.85
Reduced context effects on retrieval in first-episode schizophrenia. PLoS One (2010) 0.84
Cannabis use in patients with a first psychotic episode and subjects at ultra high risk of psychosis: impact on psychotic- and pre-psychotic symptoms. Aust N Z J Psychiatry (2010) 0.84
Marked reduction of AKT1 expression and deregulation of AKT1-associated pathways in peripheral blood mononuclear cells of schizophrenia patients. PLoS One (2012) 0.84
Disrupted dopaminergic neurotransmission in 22q11 deletion syndrome. Neuropsychopharmacology (2007) 0.84
Recent-onset schizophrenia and adolescent cannabis use: MRI evidence for structural hyperconnectivity? Psychopharmacol Bull (2009) 0.84
Factor analysis of the scale of prodromal symptoms: differentiating between negative and depression symptoms. Psychopathology (2011) 0.84
The course of parental expressed emotion and psychotic episodes after family intervention in recent-onset schizophrenia. A longitudinal study. Schizophr Res (2002) 0.84
Prescription of antipsychotic medication to patients at ultra high risk of developing psychosis. Int Clin Psychopharmacol (2009) 0.84
Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain. Hum Psychopharmacol (2008) 0.84
Incidence rates and risk factors of bipolar disorder in the general population: a population-based cohort study. Bipolar Disord (2013) 0.84
Cognitive impairment in late life schizophrenia and bipolar I disorder. Int J Geriatr Psychiatry (2012) 0.84
Cocaine is a major risk factor for antipsychotic induced akathisia, parkinsonism and dyskinesia. Psychopharmacol Bull (2008) 0.84
Social functioning among older community-dwelling patients with schizophrenia: a review. Am J Geriatr Psychiatry (2010) 0.83
Relationship between working-memory network function and substance use: a 3-year longitudinal fMRI study in heavy cannabis users and controls. Addict Biol (2013) 0.83
Subjective experiences during dopamine depletion. Am J Psychiatry (2005) 0.83
Modelling the treated course of schizophrenia: development of a discrete event simulation model. Pharmacoeconomics (2005) 0.83
Dopaminergic modulation of the human reward system: a placebo-controlled dopamine depletion fMRI study. J Psychopharmacol (2010) 0.83
The effect of childhood maltreatment and cannabis use on adult psychotic symptoms is modified by the COMT Val¹⁵⁸Met polymorphism. Schizophr Res (2013) 0.83
Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial. Can J Psychiatry (2008) 0.82
History of trauma and the association with baseline symptoms in an Ultra-High Risk for psychosis cohort. Psychiatry Res (2013) 0.82
Auditory ERP components before and after transition to a first psychotic episode. Biol Psychol (2011) 0.82
Transition to first episode psychosis in ultra high risk populations: does baseline functioning hold the key? Schizophr Res (2012) 0.82
Sensory gating in subjects at ultra high risk for developing a psychosis before and after a first psychotic episode. World J Biol Psychiatry (2012) 0.81
Cessation of cannabis use by patients with recent-onset schizophrenia and related disorders. Psychopharmacol Bull (2008) 0.81
Subjective well-being in schizophrenia as measured with the Subjective Well-Being under Neuroleptic Treatment scale: a review. Aust N Z J Psychiatry (2011) 0.81
Theory of mind, insecure attachment and paranoia in adolescents with early psychosis and healthy controls. Aust N Z J Psychiatry (2013) 0.81
Remission of schizophrenia psychosis and strong reduction of obsessive-compulsive disorder after adding clozapine to aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry (2009) 0.81
Associations between the Five-Factor Model personality traits and psychotic experiences in patients with psychotic disorders, their siblings and controls. Psychiatry Res (2013) 0.80
Evidence that transition from health to psychotic disorder can be traced to semi-ubiquitous environmental effects operating against background genetic risk. PLoS One (2013) 0.80
Suicide risk in placebo vs active treatment in placebo-controlled trials for schizophrenia. Arch Gen Psychiatry (2003) 0.80
Semantic fluency deficits and reduced grey matter before transition to psychosis: a voxelwise correlational analysis. Psychiatry Res (2011) 0.80
Striatal dopamine D2/3 receptor binding following dopamine depletion in subjects at Ultra High Risk for psychosis. Eur Neuropsychopharmacol (2012) 0.80